Neuropore Therapies, Inc.

16 articles with Neuropore Therapies, Inc.

• Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research to Support Development of Its TLR2 Program

  4/19/2022

  Neuropore Therapies, Inc. announced that it received a $4.8M grant from The Michael J. Fox Foundation for Parkinson’s Research.

• 

  Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease

  12/2/2021

  Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.

• Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

  5/17/2021

  Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies, Inc and UCB Biopharma SRL on December 31, 2014.

• Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening Diseases

  9/29/2020

  Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology. This portfolio of small molecule autophagy modulators, targeting PI3K and VPS34, was discovered by Neuropore Therapies and characterized using its comprehensive platform of autophagy and lysosomal biogenesis cellular a

• Neuropore Therapies Receives $500,000 Grant from The ALS Association to Explore ALS Treatments that Inhibit Neuronal Damage from Disease-Related Inflammation

  2/17/2020

  Feb. 17, 2020 13:01 UTC SAN DIEGO--( BUSINESS WIRE )-- Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made

• Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  1/13/2020

  Neuropore Therapies, Inc. announced that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34.

• Neuropore Therapies, Inc. Appoints Dr. Joseph S. McCracken to Board of Directors

  10/29/2019

  Neuropore is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease

• Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis

  8/14/2019

  Neuropore Therapies, Inc. announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS.

• Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence

  8/5/2019

  Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.

• UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration

  5/28/2019

  Neuropore Therapies, Inc. announced that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America.

• Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  5/8/2019

  Neuropore Therapies, Inc. announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34.

• Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research

  1/4/2018

  Neuropore Therapies announced today that it received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative disorders.

• Neuropore Therapies Awarded Grant From The Michael J. Fox Foundation For Parkinson’s Research

  1/30/2017

• Neuropore Therapies Release: SoCal Biotech Names A New CEO

  1/23/2017

• Neuropore Therapies Announces Achievement Of Key Program Milestone

  9/13/2016

• Neuropore Therapies Announces Successful Completion Of Phase I With Its Lead Compound NPT200-11

  3/22/2016